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Objectives
To determine the toxicity and NY-ESO-1-specific immune
responses induced by immunization with rV-NY-ESO-1 or
rF-NY-ESO-1.
Study design
Eligible patients (pts) for the first part of the study were
HLA-A2+ with advanced NY-ESO-1/LAGE+ tumors
assessed by RT-PCR or immunohistochemistry. For the
second part, pts were enrolled irrespective of the HLA
type. Four injections of rV-NY-ESO-1, 3.1 × 107 pfu i.d., or
rF-NY-ESO-1, 7.41 × 107 pfu s.c., were administered four
times at 4 week intervals in part 1. Pts enrolled to part 2
received 2 injections of rV-NY-ESO-1, 3.1 × 107 pfu i.d.,
followed by multiple injections of rF-NY-ESO-1, 7.41 ×
107 at monthly intervals in case there was no evidence for
progressive disease during vaccination. Toxicity was eval-
uated every 2 weeks. Delayed-type hypersensitivity (DTH)
against HLA-A2 binding NY-ESO-1 peptides was assessed
at baseline and after the last vaccination in HLA-A2+ pts.
Immunogenicity was assessed by ELISPOT and tetramer
analysis against HLA-A2 binding NY-ESO-1 peptides.
Results
29 pts with different types of cancer were enrolled, 9 pts
are ongoing, 11 completed at least 4 cycles of treatment, 9
were withdrawn for disease progression or at their own
discretion. No remarkable toxicities occured. Positive
post-vaccination DTH reactions against 2 HLA-A2 binding
NY-ESO-1 peptides occurred in 6/6 pts tested. At baseline
all HLA-A2+ pts of part 1 were NY-ESO-1 serum antibody-
and CD8+ T-cell negative. In 2 pts a conversion of NY-
ESO-1 serum antibody was observed after 3 vaccinations.
In 9 pts for whom immune assay data are available, NY-
ESO-1 specific CD8+ T-cell responses were induced during
vaccination. After 4 injections maximum ELISPOTS
ranged between 160–800 per 50,000 CD8+ T-cells in the 2
vaccinia pts and 100–500 in the 2 fowlpox pts as con-
firmed by tetramer assays. At 4 months 14 pts were found
to have stable disease. 1 pt experienced a partial remission
of subcutaneous and peritoneal melanoma metastases
after 3 months of immunization. Assessments are under-
way for NY-ESO-1 specific T cell responses restricted by
non-HLA-A2 and HLA class II alleles.
Conclusion
Immunization with recombinant vaccinia- and fowlpox-
NY-ESO-1 is safe and induces NY-ESO-1 specific immune
responses.
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